Resveratrol inhibiting TGF/ERK signaling pathway can improve atherosclerosis: backgrounds, mechanisms and effects

Area of Science:

• Cardiovascular Science
• Molecular Biology
• Pharmacology

Background:

• Atherosclerosis (AS) is a primary cause of cardiovascular and cerebrovascular diseases, posing a significant global health challenge.
• Current AS treatments are limited due to complex factors like multiple risks, lesion intricacy, and patient variability.
• Signal transduction pathways, including transforming growth factor/extracellular regulated protein kinases (TGF/ERK), are critical in AS development and progression.

Purpose of the Study:

• To review the therapeutic potential of resveratrol in treating atherosclerosis.
• To explore the role of the TGF/ERK signaling pathway in AS pathogenesis.
• To summarize research on resveratrol's anti-atherosclerotic effects via modulating the TGF/ERK pathway.

Main Methods:

• Literature review of studies investigating resveratrol's effects on atherosclerosis.
• Analysis of research focusing on the TGF/ERK signaling pathway in AS.
• Synthesis of evidence on resveratrol's mechanisms of action, including lipid regulation, anti-inflammation, and oxidative stress reduction.

Main Results:

• Resveratrol demonstrates beneficial effects across various AS stages.
• The compound modulates lipid metabolism, reduces inflammation, and alleviates oxidative stress.
• Evidence suggests resveratrol's anti-atherosclerotic effects are linked to the inhibition of the TGF/ERK signaling pathway.

Conclusions:

• Resveratrol holds significant therapeutic potential for atherosclerosis.
• Modulating the TGF/ERK pathway is a key mechanism for resveratrol's anti-atherosclerotic actions.
• Further research into resveratrol could lead to novel treatments for cardiovascular diseases.